CoChat

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

Moreau, Philippe, Attal, Michel, Pégourié, Brigitte, Planche, Lucie, Hulin, Cyrille, Facon, Thierry, Stoppa, Anne-Marie, Fuzibet, Jean-Gabriel, Grosbois, Bernard, Doyen, Chantal, Ketterer, Nicolas, Sebban, Catherine, Kolb, Brigitte, Chaleteix, Carine, Dib, Mamoun, Voillat, Laurent, Fontan, Jean, Garderet, Laurent, Jaubert, Jérôme, Mathiot, Claire, Esseltine, Dixie, Avet-Loiseau, Hervé, Harousseau, Jean-Luc, for the IFM 2005-01 study investigators* · 2011 · Blood
Cited by 123

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

In the 2005-01 trial, we have demonstrated that bortezomib-dexamethasone as induction therapy before autologous stem cell transplantation was superior to vincristine-adriamycin-dexamethasone. We conducted a post-hoc analysis to assess the prognostic impact of initial characteristics as well as response to therapy in patients enrolled in this study. Multivariate analysis showed that ISS stages 2 and 3 and achievement of response less than very good partial response (VGPR) both after induction therapy and after autologous stem cell transplantation were adverse prognostic factors for progression-free survival, the most important one being achievement of response less than VGPR after induction. Progression-free survival was significantly improved with bortezomib-dexamethasone induction therapy in patients with poor-risk cytogenetics and ISS stages 2 and 3 compared with vincristine-adriamycin-dexamethasone. In these 2 groups of patients, achievement of at least VGPR after induction was of major importance. This study is registered with EudraCT (https://eudract.ema.europa.eu; EUDRACT 2005-000537-38) and http://clinicaltrials.gov (NCT00200681).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-08-300863

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 123

Metadata

Authors
Moreau, P., Attal, M., Pégourié, B., Planche, L., Hulin, C., Facon, T., Stoppa, A.-M., Fuzibet, J.-G., Grosbois, B., Doyen, C., Ketterer, N., Sebban, C., Kolb, B., Chaleteix, C., Dib, M., Voillat, L., Fontan, J., Garderet, L., Jaubert, J., Mathiot, C., Esseltine, D., Avet-Loiseau, H., Harousseau, J.-L., & for the IFM 2005-01 study investigators*
Venue
Blood
Published
2011-03-17
Volume
117
Issue
11
Pages
3041-3044
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1983715506
Cited by
123
References
6
FWCI
6.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. https://app.cochat.ai/papers/10.1182/blood-2010-08-300863
The paper
Moreau, P., Attal, M., Pégourié, B., Planche, L., Hulin, C., Facon, T., Stoppa, A.-M., Fuzibet, J.-G., Grosbois, B., Doyen, C., Ketterer, N., Sebban, C., Kolb, B., Chaleteix, C., Dib, M., Voillat, L., Fontan, J., Garderet, L., Jaubert, J., . . . for the IFM 2005-01 study investigators*. (2011). Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood. https://doi.org/10.1182/blood-2010-08-300863

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.